RENOVARO
LIVE LONGER

AI Driven Precision Medicine

Better outcomes through knowledge

NASDAQ: RENB

April 2025

Forward Looking Statements

Statements in this presentation that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Renovaro's mission is to find the right treatment for every patient

We are leveraging our AI platform to better understand individual patients, recommending the best treatment options and building new personalized therapeutics

REN-AI: A translational platform for precision medicine and drug discovery

Our proprietary AI platform allows us to better understand patients and use this knowledge to drive treatment selection and discovery of new therapies



ENABLED BY PATENTED

CONTINGENT AI™

REN-AI: A translational platform for precision medicine and drug discovery



CONTINGENT AI is the patented core technology that deploys machine learning through automated pre-processing pipelines of thousands of models and hyperparameter optimization that results in novel data clustering and robust features.

CLINICAL INSIGHTS

Patented AI process to analyze complex patient datasets, identifying clinically-relevant patient sub-groups.

GEDI CUBE

Use proprietary deep learning models based on multi-omic data to identify novel biomarkers for disease diagnosis and progression.

PHENOGRAPH

Hundreds of proprietary models used to interpret complex biology and prioritize disease pathways, identifying targets.

VALIDATION & SCREENING

Validate disease drivers and population-specific signals and identify new therapeutics in vivo through AI-driven screening.

Renovaro is unique in the precision medicine and drug discovery space

Renovaro has a unique platform for data standardization and integration and is the only tech bio company that couples sophisticated AI predictions with scalable validation in living organisms. Experiments are efficiently driven through AI and validated at low costs and with fast timelines.



REN-AI: Precision Neurology

Epilepsy

Epilepsy genes prioritized using proprietary ML models



ML models are trained to predict gene-phenotypes and aggregate scores suggested KCC2

In vivo KCC2 epilepsy model developed, and library screened



Hypofunction of KCC2 caused a measurable response to a light stimuli (both genetic and chemical models)

Hit compounds rescue the seizure phenotype



In vivo zebrafish hit data demonstrates good efficacy, evidence of blood-brain barrier penetrance, and no observable toxicity

REN-AI: Precision Neurology

Epilepsy

Partnership: Drug repurposing using targeted genetic manipulation and in vivo screening





Results & Impact:

- Drug reversed seizures in 2 genetic models
- Partner used zebrafish data for FDA submission
- Phase 2 trial in DRE is being launched using patient stratification strategy informed by genetic models

Supernus® Pharmaceuticals

REN-AI: Precision Neurology

Parkinson's Disease

Identifying biomarkers associated with milestones of Parkinson's Disease

- Identified 9 patient sub-groups among PD patients, each with unique characteristics and clinical signals
- Proprietary ML models can predict membership into any of these groups for new patients with high accuracy
- Using these sub-groupings we have identified clinical biomarkers





REN-AI: Precision Oncology

Lung cancer

Liquid biopsy

Development Milestones

#4

Introduce platform to wider audience

Commercialize the platform by targeting healthcare providers, researchers, and patients, driving widespread adoption.

#3

Large-scale testing with liquid biopsy

Scale liquid biopsy testing to diverse populations, refining accuracy and expanding coverage to validate the platform across various cancer types.

Validated by eureka eurostars

#2

Small-scale test with liquid biopsy

Achieved 70% accuracy in identifying lung cancer through deep learning-powered liquid biopsy analysis, demonstrating proof-of-concept and diagnostic potential.

#1

Extract biomarkers from Tissue Samples

Developed a robust biomarker engine to extract and identify cancer-specific biomarkers from tissue samples, creating a comprehensive database for diagnostic development.

REN-AI: Precision Oncology

Pancreatic cancer

Allogeneic CD34+ derived; gene modified dendritic cell therapy

- DCs loaded with patients' tumor lysate and can activate strong immune system against multiple tumor antigens
- Multiple cancer antigen recognition. Highly potent. No immune suppression.
- Initial studies show mouse efficacy in pancreatic cancer model (right), additional indication screening underway
- REN-AI to provide further improvements by identifying TAA/Neo Ag panels to transfer DCCV to a fully off-the-shelf treatment and as companion diagnostic, and identifying additional allogenic factors to enhance potency



Pipeline of therapeutic candidates

Pre-clinical pipeline of therapeutics derived through patient insight

THERAPEUTIC AREA	NAME	INDICATION	TARGET
Cancer	RENB-001	Pancreatic Cancer	Undisclosed
	RENB-002	Lung Cancer	Undisclosed
Neurology	RENB-008	Epilepsy	Undisclosed
	RENB-009	Epilepsy	Undisclosed



Market Opportunity

PRECISION MEDICINE MARKET 2022-2030

Global Market Size 2022 ($B)	Market growth will **ACCELERATE** at a **CAGR of**	**Global** Market Size 2030 ($B)
73.49 B	**11.5%**	**175.64 B**

AI in ONCOLOGY MARKET 2022-2030

Global Market Size 2022 ($M)	Market growth will **ACCELERATE** at a **CAGR of**	**Global** Market Size 2030 ($B)
838.7 M	**34.6%**	**9.58 B**

AI in PRECISION MEDICINE MARKET 2022-2030

Global Market Size 2021 ($M)	Market growth will **ACCELERATE** at a **CAGR of**	**Global** Market Size 2030 ($B)
946 M	**35.7%**	**14.53 B**

AI in GENOMICS MARKET 2022-2030

Global Market Size 2022 ($B)	Market growth will **ACCELERATE** at a **CAGR of**	**Global** Market Size 2030 ($B)
0.39 B	**40.3%**	**5.97 B**

Source: Grand View Research

Renovaro uses a pre-clinical licensing model that can lead to substantial revenue

AVERAGE TOTAL DEAL VALUE FOR PRE-CLINICAL LICENSING DEALS IN NEUROLOGY



- 15 licensing deals in 2023 for neurology-specific pre-clinical assets[1]
- Total Deal Value (TDV), which includes success-based milestones, averaged $880M per deal in 2023
- The average upfront payment for these deals was $26M in 2023

1. https://www.bio.org/ia-reports/emerging-therapeutic-company-investment-and-deal-trend

* Based on data through Q2

Our Board

Maurice van Tilburg
Chairman

Maurice van Tilburg is the former Director of the Dutch National Growth fund where he oversees the largest government investments in the area of innovation and technology. Mr. van Tilburg was formerly the CEO of Euronext Amsterdam.

David Weinstein
CEO & Director

While at Dawson James, Mr. Weinstein directly sourced over $300 million in investments for small-cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq.

Douglas W. Calder
Director

Since 2015, Mr. Calder has served as president and a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as a member of the board of directors for Zevra Therapeutics, Inc. (NASDAQ: ZVRA) since April 2023; member of the board of directors for NextGenNK since June 2019; member of the board of directors of BioFlorida since January 2019, and a member of the Society for Natural Immunity since July 2018.

Mark A. Collins, PhD
Director

Dr. Collins has dedicated his 40-year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a company that takes a unique AI-driven clinically informed, network-medicine approach to repurposing existing drugs for acute and chronic neuropathic pain conditions.

James A. McNulty
Director

Mr. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26-year career in Tampa as founder of three CPA firms, he served as CFO in the biopharmaceutical industry, including 3 years with Star Scientific (NASDAQ: STSI) and 15 years with BioDelivery Sciences International (NASDAQ: BDSI).

Near Term Key Developments



Investment Summary

- **Long Term Goal:** Deliver a point of care solution for multi-cancer early detection from a simple blood draw - when cancer is detected to deliver a personalized cancer therapy
- **Inflection Point in Medicine:**
  - 90% of cancers could be effectively treated if diagnosed in an early stage
  - Nvidia's latest chip sets make it possible to run the trillions of calculations needed for early cancer detection & personalized cancer vaccines, drug discovery and repurposing existing drugs
- **Innovative Technology:** Next generation deep learning AI/ML systems for drug discovery and diagnostics
- **New Leadership:** Team of technology, biotechnology and pharmaceutical experts driving new focus and strategy

News

RENB
NASDAQ Listed

Shares Outstanding	158.7M
Contingent shares pro rata upon the exercise of convertible notes, options, and warrants	11.9M
Sector	Healthcare
Industry	Biotechnology
Fiscal Year End	June 30

News Releases

- Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine- Apr 9, 2025
- Provides Update to Definitive Agreement with Predictive Oncology- Apr 4, 2025
- Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology- Mar 3, 2025
- Announce definitive merger agreement with BioSymetrics - Feb 26, 2025
- Issues Shareholder Letter and Provides Corporate Update - Nov 04, 2024
- Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing - Oct 17, 2024
- Announces Strategic Restructuring and Leadership Transition - Oct 16, 2024
- Personalaize and Cube Forge Groundbreaking Partnership to Accelerate Ai-Driven Healthcare Platform and Point of Care Diagnostics - Sep 19, 2024
- Independent Expert Assessment Validates RenovaroCube'S Potential as a Groundbreaking AI Platform - September 17, 2024
- Announces $10 Million In Equity Committed - Jun 14, 2024
- Renovaro and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 24, 2024
- Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics - Apr 30, 2024

Upcoming & Past Events

- BIO 2025 – June 16-19, 2025
- European Society for Medical Oncology (ESMO) Congress – September 15, 2024
- Molecular Analysis for Precision Oncology Congress – October 16, 2024

RENOVARO

LIVE LONGER

AI Driven Precision Medicine

Better outcomes through knowledge

Investor Relations
Chris Tyson
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us

NASDAQ: RENB

April 2025

renovarogroup.com

Supplement

BioSymetrics

PERSONALIZE

REN-AI: Therapeutic discovery

Using patient-derived biomarkers and gene targets to inform novel therapeutic discovery

The **Phenograph** uses AI/ML to identify whitespaces in therapeutic development, and translate clinical signals into therapeutically developable drug targets

329
Gene-Disease Prioritization prediction models

77%
Of data is proprietary and AI-derived

11.3M
Graph Edges, or associations

29k
Diseases or Phenotypes

Pfizer MERCK DEERFIELD® Advancing Healthcare®



REN-AI: Precision Oncology

Glioblastoma

Changes in **gene expression** occur due to interaction with tumor microenvironment

Tumor signals induce **alternative splicing** of pre-RNA transcripts



Tumors can induce **thrombocytosis -** high platelet count

Circulating tumor RNA can be picked up by platelets

Current Approach

Only gene expression

Gene-expression is the only feature analyzed, disregarding potentially important cancer signals

Prone to Batch Effects

Suffers from batch effects and artifacts due to limited amount of training data

Relies on feature selection

Features must be carefully chosen prior to machine learning



Our Approach

Considers all RNA signals

Alternative splicing, mutation and gene expression changes can be taken into consideration

Resilient to batch effects

Deep-learning algorithms may be less prone to batch effects due to pretraining on larger volumes of data

Feature selection not required

Feature selection prior to machine learning is not required

REN-AI: Patient characterization

Range of AI models, algorithms and in vivo biology to truly understand patient phenotypes

CHARACTERIZE

Liquid biopsy

Draw Blood Sample: A minimally invasive liquid biopsy is performed to collect blood sample for analysis.

Identify Biomarkers: Advanced diagnostic tools analyze the sample to detect cancer-specific biomarkers with high precision.

Generate Medical Report: AI-driven insights are compiled into a comprehensive report outlining diagnostic findings and actionable data.

Determine Treatment: Clinicians use the report to tailor a personalized treatment plan based on the patient's unique cancer profile.

CHARACTERIZE

REN-AI: Patient characterization

Range of AI models and algorithms to truly understand patients

Data

Download and process data from pan-cancer and glioblastoma studies

Deep Learning

Design, build and train Deep learning algorithms on RNA derived from TEP

Classification

Fine-tune models to classify progression versus pseudo-progression

Validation

Validate model performance on an independent glioblastoma cohort provided by UMC



LLM Implementation



DCCV Competitive Landscape

Renovaro DCCV platform: the only CD34+ derived gene-modified allogeneic dendritic cell therapy

Dendreon
- Autologus DCs
- PCP antigen. PCa

FDA Approved. *USA*

Amphera
- Autologus DCs
- Peptide Ag. Pancreatic cancer
- USA

Coimmune
- Autologus DCs
- RCC-mRNA
- USA

JW CreaGene
- Autologus DCs
- CTP-conjugated TAA
- Liver/RCC
- KOREA

Jonsson Comprehensive Cancer Center & Merk
- Autologus DCs
- Lung/NSSLC/Meso
- USA

Indications



RenovaroBio
- **Gene-modified, CD34+ derived DCCV**
- **Maximizes likelihood of clinical benefit with relevant pan-tumor Ag**
- **Maximizes treatment effect/potency with genetic enhancements**

Northwest Biotherapeutics
- Autologus DCs
- Whole tumor lysate
- GBM
- USA

Aivita Biomedical
- Autologus DCs
- Whole tumor lysate
- GBM/Melanoma
- USA

- **Mendus** (acquired DC Prime) (Sweden, public SV)
  - Eng. cancer line to express DC markers, co-injected with alloDC
- EU

Genzyme/Sanofi
- Allo DCs
- RCC
- USA

RENB DCCV Personalized Medicine



Indications:

- **Pancreatic**
- **TNBC: Triple Negative Breast Cancer**
- **Prostate Cancer**
- **NSCLC**

DCCV Early Clinical Development Plan

Pre-IND communication with the FDA completed. Currently working towards submitting an IND

Pre-clinical evaluation

Pre-IND meeting with the FDA

In-process for IND-filing with the FDA

Clinical path: *First-in-Human Open Label Ascending Dose Study in Multiple Solid Tumors*

Phase I

- Up to 18 patients
- Pancreatic, TNBC, Prostate, NSCLC
- Indications with unmet need
- Characterize Safety of DCCV
- Evaluate and select dose level
- Identify early signs of efficacy

RMAT or other designation

Based on overall response

Pivotal Phase II

- Up to 40 patients (10/indication)
- Pancreatic, TNBC, Prostate, NSCLC
- Confirm efficacy data

BLA